We have assembled an experienced management team with deep expertise in oncology, immunology, clinical and regulatory development. Our business leaders and scientific advisors bring all the skills and experience from world-leading organizations to deliver novel immunotherapies

Management Team & Advisory Board

Borys Shor, Ph.D.

Chief Executive Officer

Robert Easton

Board Of Directors
Business Strategy

Yossef Av-Gay, Ph.D.

Scientific Co-Founder
Scientific Advisor

Full Professor, Division Of Infectious Diseases,
The University of British Columbia

William Johnson

VP, Finance & Corporate Development

Jules Mitchell, Ph.D.

VP, Clinical & Regulatory Strategy

John Mohr

VP, Commercial & Licensing

Scientific Advisory Board

Biologic Therapies

Dhaval Shah, Ph.D.

Scientific Advisor
Antibodies & ADCs

Associate Professor, Pharmaceutical Sciences,
University at Buffalo, New York

Nathan Tumey, Ph.D

Scientific Advisor
Antibody Drug Conjugates

Assistant Professor, Pharmaceutical Sciences,
Binghamton University, New York

Jean Kadouche, Ph.D

Scientific Advisor
Antibody Development


Microbial Immunity

Jessica Seeliger, Ph.D.

Scientific Advisor
Microbial Biochemistry

Associate Professor, Pharmacological Sciences,
Stony Brook University, New York

Claudia Cravekamp, Ph.D

Scientific Advisor

Associate Professor, Microbiology & Immunology,
Albert Einstein College Of Medicine, New York

Anna Bunin, Ph.D

Scientific Advisor


Dr. Shor has 15 years of experience in leading oncology discovery programs and external R&D partnerships at large pharmas (Wyeth, Pfizer) and biotech companies, with specific focus on preclinical discovery and development of biologics, small molecule kinase inhibitors and nanoparticles. He is a founder and the CEO of Manhattan BioSolutions Inc. Dr. Shor also serves as a BioEntrepreneur-In-Residence with the New York State Biotechnology Center in Long Island and is a founder of BioIDEA, a biotech pitching forum in New York City. Previously at Pfizer, Boris led cross-functional oncology research teams to develop novel antibody-drug conjugates and supported Biological License Application (BLA) filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, Dr. Shor served as a project team leader at the department of Oncology Discovery at Wyeth Pharmaceuticals, managing the discovery and characterization of novel mTOR/PI3K kinase inhibitors for the treatment of cancer.

Dr Shor earned M.S. degree in molecular genetics from the St. Petersburg State University. He also received a Ph.D. in Molecular and Cell Biology at the SUNY Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Wyeth

Bob has been recognized as a thought leader in medical business strategy for almost forty years. Bob was formerly co-chairman of Bionest Partners. Prior to that, he built and led two other consulting firms, The Wilkerson Group and Easton Associates. Bob has led strategy development and supervised opportunity assessments for hundreds of clients on four continents, including large and specialty pharmaceutical companies, early-stage through publicly-traded biopharmaceutical companies, and diagnostics businesses. He is past chairman of the New York Biotechnology Association and has served on ten medical company boards. He also serves as past chairman of Gilda’s Club of New York City. Bob holds degrees in chemical engineering from Rice University and an MBA from the Harvard Business School.